Results

Total Results: 1,544 records

Showing results for "drug".

441. Disposition of Comments for Comparative Effectiveness Review No. 240: Treatments for Acute Pain: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-revised-comments.pdf
     December 29, 2020 - In response to the comment from the Food and Drug Administration, a number of sections throughout the … We see our drs, take our meds accordingly, and take random drug tests. … I also noticed cases were not consistent in the drug comparison. … Not just people and doctors who are involved ONLY in rehab facilities , drug companies and insurance … • Acetaminophen is not a risk-free drug.

442. PHS 398 (Rev. 9/04), Continuation Page (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/administrative-data-validity_research.pdf
     January 01, 2007 - A study funded by the US Food and Drug Administration and performed by the Research Triangle Institute … physician offices, pharmacies, etc.1 The results of this study suggested that the demographic and drug … As this study was conducted supplementary to an ongoing R01 investigating drug-induced SCD/VA, this … Incidence and antecedent drug exposures. Arch. Dermatol. 127, 831-838 (1991). 4.

443. PHS 398 (Rev. 9/04), Continuation Page (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/upenn-final-report-2005-certs-ce-supplement.pdf
     January 01, 2005 - A study funded by the US Food and Drug Administration and performed by the Research Triangle Institute … physician offices, pharmacies, etc.1 The results of this study suggested that the demographic and drug … As this study was conducted supplementary to an ongoing R01 investigating drug-induced SCD/VA, this … Incidence and antecedent drug exposures. Arch. Dermatol. 127, 831-838 (1991). 4.

444. Antipsychotics-Adults Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antipsychotics-adults_surveillance.pdf
     August 30, 2014 - Question 3: Conclusions regarding findings related to adverse events are out of date due to a new drug … would produce prima facie evidence that a conclusion was out of date, such as the withdrawal of a drug … Question 3: Conclusions regarding findings related to adverse events are out of date due to a new drug … Antipsychotic Agents/ 119338 26 exp Tranquilizing Agents/ 197439 27 (neuroleptic adj2 (agent* or drug … ed.ab. 335140 118 placebo*.ab. 149301 119 drug therapy.fs. 1651625 120 randomly.ab. 204443 121

445. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/introduction-to-user-guide-overview.pptx
     January 01, 2013 - Availability of comparative efficacy data at the time of drug approval in the United States. … To address the need for outcomes research, Section 1013 of the Medicare Prescription Drug, Improvement … Recognizing the need for outcomes research, Section 1013 of the Medicare Prescription Drug, Improvement … Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L.

446. Crosscutting-Horizon-Scan-High-Impact-1406 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1406.pdf
     June 01, 2014 - Food and Drug Administration (FDA) through the premarket approval process. … Food and Drug Administration (FDA)-approved labeling for propofol states that the drug “should be administered … Food and Drug Administration (FDA); 2009 May 28. 32 p. … Food and Drug Administration (FDA); 2010 Mar 25 [accessed 2010 Dec 27]. [10 p]. … Food and Drug Administration (FDA); 2012 May 14. 10 p.

447. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/type-2-diabetes-medications-update_research-protocol.pdf
     April 06, 2010 - sufficiently homogenous with respect to key variables (population characteristics, study duration, and drug … Food and Drug Administration In response to comments received on the posted Key Questions, the following … In addition to the possible interventions, the comparators include any insulin, non-drug interventions … We also plan to tally studies that compare either an alpha-glucosidase inhibitor or a non-drug intervention … Interventions □ All studies must have evaluated an oral diabetes medication or drug combination of interest

448. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/selection-of-data-sources-chapter-8.pptx
     January 01, 2013 - Claims submitted to insurance companies for payments, as well as pharmacy dispensing records National Drug … pharmacy data include claims submitted to insurance companies for payment, as well as the records on drug … Food and Drug Administration has authority over the NDC numbers. … Food and Drug Administration (FDA) has a vast store of data from regulatory approval submissions. … Food and Drug Administration (FDA) has a vast store of data from submissions for regulatory approval

449. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hypothyroidism-hyperthyroidism-screening-treatment_research-protocol.pdf
     March 11, 2010 - www.effectivehealthcare.ahrq.gov/� Source: www.effectivehealthcare.ahrq.gov Published Online: March 11, 2010  Drug …  Drug Class: Synthetic version of thyroxine (T4) and triiodothyronine (T3); Generic name: Liotrix …  Drug/Biologic Class: Porcine thyroxine (T4) and triiodothyronine (T3); Generic name: Natural thyroid … o Hyperthyroid Treatment:  Drug Class: Methimazole - Inhibits the thyroid from using iodine to … Generic Names: Methimazole (Brand name: Tapazole) and Carbimazole (Brand name: Neo-Mercazole)  Drug

450. Prioritization and Selection of Harms for Inclusion in Systematic Reviews (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-selection-harms-systematic-reviews.pdf
     February 01, 2018 - Less serious but common and bothersome harms such as a drug induced dry cough, diarrhea, or dizziness … another but the drug with a lower risk of overall serious adverse events increases mortality versus … A vs. drug B) Presenter Presentation Notes Use Prioritization Process to Narrow Number of Harms to … Evaluating drug effects in the post-Vioxx world there must be a better way. … Evaluating drug effects in the post-Vioxx world there must be a better way.

451. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/atrial-fibrillation_research-protocol.pdf
     May 22, 2012 - We will use several approaches to identifying relevant gray literature, including requests to drug and … Food and Drug Administration (FDA) device registration studies and new drug applications. … A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in … Food and Drug Administration HRS Heart Rhythm Society ICTRP International Clinical Trials Registry … of interest, unless the study also includes a comparison between a drug of interest and a control

452. Liver-Cancer-Therapy Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/liver-cancer-therapy_research-protocol.pdf
     November 28, 2012 - Tumor ischemia raises the drug concentration, prolongs the retention of the chemotherapeutic agent, … o Drug-eluting beads (DEBs) are a novel transarterial embolization system in which a drug-loaded (typically … into the tumor, allowing longer intratumoral exposure and less systemic exposure to the drug.20 … Abbreviations: DEBs = drug-eluting beads; HCC = hepatocellular carcinoma; MWA = microwave ablation; … Food and Drug Administration (FDA) Web site, and relevant conference abstracts (conferences identified

453. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1406.pdf
     February 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … trigeminal neural pathways, bypassing the blood-brain barrier and reducing systemic exposure to the drug … various delivery methods, including needleless syringes inserted into alternating nostrils, a nasal drug … Food and Drug Administration (FDA) for treating diabetes, including Humulin® and Humulin R® (Eli Lilly … -based, online aggregator of prescription-drug prices lists prices ranging from $25 to $250 for a single

454. Ch 6-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_6-user-guide-to-ocer_130129.pdf
     October 30, 2012 - Food and Drug Administration (FDA) has provided input on types of Clinical Outcome Assessments (COAs … “no blood, no drug” monitoring program. … Department of Health and Human Services, Food and Drug Administration. … Department of Health and Human Services, Food and Drug Administration. … Department of Health and Human Services, Food and Drug Administration.

455. Searching for Relevant Studies (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/searching.ppt
     January 01, 2011 - reaction /drug toxicity /complication Consider using a database dedicated to harms such as TOXNET … Regulatory Web sites: Drugs@FDA; https://www.accessdata.fda.gov/scripts/cder/daf/ Health Canada Drug … In lines 24 and 25, the drug classes of ACE inhibitors and angiotensin II type-1 receptor blockers are … In lines 17, 18, and 19 we search for the drug classes. 17. … In lines 17, 18, and 19 we search for the drug classes. 17.

456. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation-ablation_disposition-comments.pdf
     October 01, 2010 - Food and Drug Administration. Circulatory Devices Panel Meeting: Briefing Information. 2008. … any episode lasting >3 min. after up to 3 ablation procedures or changes in drug therapy within the … In this study, which allowed for concomitant AAD use with a previously ineffective drug after RFA, the … Food and Drug Administration. Circulatory Devices Panel Meeting: Briefing Information. 2008. … Food and Drug Administration. Circulatory Devices Panel Meeting: Briefing Information. 2008.

457. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis—An Update of the 2006 Report. (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-disposition-120516.pdf
     October 01, 2011 - I believe it makes sense to first compare a drug category to placebo/no Rx and then to other agents … Salsalate was selected as an included drug for this review. … also be mentioned that PPI have numerous adverse effects, among them: - Increase the potential of drug-drug … Drug- induced osteoporosis: mechanisms and clinical implications. … Diagnosis of drug-induced psoriasis. Semin Dermatol. 1992;11:269e74. Ben-Chetrit E, Rubinow A.

458. S103 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s103.pdf
     October 01, 2007 - Consider the effect of era in the use of drug-eluting stents for the treatment of coronary artery ste … Drug-eluting stents prevent restenosis by delivering drugs locally to inhibit scar formation. … Despite little evidence regarding the long-term effectiveness of drug-eluting stents compared with bare … metal stents, drug-eluting stents have become the pri- mary mode of coronary revascularization in the … to receive a drug-eluting stent.

459. Disposition of Comments Report for Comparative Effectiveness Review No. 131 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/crohns-disease_disposition-comments.pdf
     February 25, 2014 - on “which drug should we use for relief at timepoint Y”. … This was used to determine “favors neither” or “favors specified drug.” … 8-12 if you don’t include the one trial with only a single dose of the drug. … We list what the current approved route is for each drug. … The tables are already broken out by key question, and are labeled by type of drug.

460. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/crohns-disease_research-protocol.pdf
     September 01, 2010 - September 01, 2010 AND (agent*[tiab] OR treatment*[tiab] OR treated[tiab] OR therap*[tiab] OR drug … sufficiently homogenous with respect to key variables (population characteristics, study duration, and drug … We will attempt to conduct NMA to compare relative effects of different drug classes and of different … agents within a drug class. … Definition of Terms CD = Crohn’s disease CDAI = Crohn’s disease activity index FDA = Food and Drug